Grifols (GRFS) P/B (2011 - 2026)
Grifols (GRFS) P/B from Jun 2, 2011 to Jun 3, 2026. The TTM Grifols (GRFS) P/B is 0.81. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/B
Annual P/B change of Grifols (GRFS)
| Year | P/B | Change |
|---|---|---|
| 2026 | 0.81 | -21.67% |
| 2025 | 1.03 | +23.73% |
| 2024 | 0.83 | -31.98% |
| 2023 | 1.22 | -92.20% |
| 2022 | 15.66 | +1196.65% |
| 2021 | 1.21 | -40.18% |
| 2020 | 2.02 | -20.70% |
| 2019 | 2.55 | -1.76% |
| 2018 | 2.59 | -30.57% |
| 2017 | 3.73 | +36.61% |
| 2016 | 2.73 | -11.64% |
| 2015 | 3.09 | -15.41% |
| 2014 | 3.66 | -13.25% |
| 2013 | 4.22 | +20.07% |
| 2012 | 3.51 | +121.24% |
| 2011 | 1.59 | N/A |
Comparison Grifols (GRFS) P/B with competitors
Grifols (GRFS) P/B is 0.81.
| Ticker | Name | P/B | Upside |
|---|---|---|---|
| AMRN | Amarin Corp | 0.67 | -17.19% |
| SNY | Sanofi | 1.25 | +55.44% |
| BIIB | Biogen Inc | 1.55 | +92.93% |
| PFE | Pfizer Inc | 1.66 | +105.84% |
| OGN | Organon & Company | 3.88 | +381.95% |
| GSK | GSK Plc | 4.30 | +433.35% |
| MIRA | Mira Pharmaceuticals Inc | 4.90 | +508.21% |
| BMY | Bristol-Myers Squibb Company | 5.91 | +633.73% |
| AZN | Astrazeneca plc | 6.07 | +653.59% |
| NVO | Novo Nordisk | 6.24 | +674.70% |
| MRK | Merck & Co Inc | 6.47 | +703.25% |
| JNJ | Johnson & Johnson | 6.86 | +751.67% |
| GILD | Gilead Sciences Inc | 7.06 | +776.50% |
| NVS | Novartis AG | 7.49 | +829.88% |
| MDCX | MDCorp | 13.18 | +1536.30% |
| NSRX | Nasus Pharma Ltd | 14.22 | +1665.41% |
| AMGN | AMGEN Inc | 19.74 | +2350.72% |
| SCLX | Scilex Holding Company | 28.85 | +3481.73% |
| LLY | Lilly(Eli) & Company | 30.95 | +3742.44% |
| ABBV | Abbvie Inc | 50.46 | +6164.60% |